RxDoctor Payments Data

Humberto Nunez Uriburu, MD

Family Medicine · McAllen, TXNPI 1992952261

Payments from drug & device makers

$1,852in general payments, 2019–2025

Across 31 payments — averaging $59.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$363
  • E.r. Squibb & Sons, L.L.C.$343
  • Melinta Therapeutics, LLC$214
  • AbbVie$182
  • AstraZeneca$147
  • Otsuka America Pharmaceutical, Inc.$121
  • plus $482 from 7 others

What the payments were for

  • Food & beverage$1,852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,852 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$419,676
Medicare patients
694
Services billed
4,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban645$196,021
CreonLipase/Protease/Amylase67$81,030
XareltoRivaroxaban271$76,392
XifaxanRifaximin60$74,404
JanuviaSitagliptin Phosphate162$60,917
JardianceEmpagliflozin197$58,202
EntrestoSacubitril/Valsartan104$35,842
TradjentaLinagliptin99$27,996
FarxigaDapagliflozin Propanediol74$22,518
Sevelamer Carbonate103$20,247
SantylCollagenase Clostridium Hist.40$19,034
Tresiba Flextouch U-100Insulin Degludec83$18,189
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,645
Memantine Hcl699$16,978
Atorvastatin Calcium1,215$15,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$196,021645 claims
AbbVieCreon, Linzess, Namzaric$182$95,74099 claims
Johnson & JohnsonXarelto, Invokana$363$83,831298 claims
MerckJanuvia$17$60,917162 claims
NovartisEntresto$116$35,842104 claims
AstraZenecaFarxiga$147$22,51874 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →